Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

Doctors and patients have been hoping for a pill version that would be easier to take, in contrast to an injectable.

The latest discovery in obesity medicine will be available in less invasive creams and patches, known as transdermal drug ...